CD276 and neoplasm: The favourable imaging properties of Affibody molecules were confirmed by development of the B7-H3 imaging probe [99mTc]Tc-ZAC12−GGGC (Oroujeni et al. 2022), which in a mouse model provided better tumour-to-blood ratio (11.0 ± 0.5) already 4 h after injection than the conventional antibody-based tracer 89Zr-DS-5573a (Burvenich et al. 2018) provided 7 days after injection (5.03 ± 0.73).